General Information of Drug (ID: DMQ8FR2)

Drug Name
Prednisolone
Synonyms
Nanocort; Prednisolone (injectable liposome formulation, rheumatoid arthritis); Prednisolone (injectable liposome formulation, rheumatoid arthritis), Enceladus; Prednisolone (injectable liposome formulation, rheumatoid arthritis), Galapagos
Indication
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [1]
Acute asthma CA23 Approved [1]
Addison disease 5A74.0 Approved [1]
Allergic rhinitis CA08.0 Approved [1]
Angioedema 4A00.15 Approved [1]
Aspiration pneumonitis N.A. Approved [1]
Autoimmune haemolytic anaemia 3A20 Approved [1]
Blepharoconjunctivitis N.A. Approved [1]
Bursitis N.A. Approved [1]
Cerebral edema 8D60.1 Approved [1]
Chronic graft versus host disease N.A. Approved [1]
Congenital adrenal hyperplasia 5A71.01 Approved [1]
Corneal abrasion NA06.4 Approved [1]
Corneal ulcer 9A76 Approved [1]
Crohn disease DD70 Approved [1]
Dacryocystitis N.A. Approved [1]
Demodex blepharitis 1G07 Approved [1]
Dermatitis herpetiformis EB44 Approved [1]
Diamond-Blackfan anemia N.A. Approved [1]
Disorder of orbital region N.A. Approved [1]
Epicondylitis N.A. Approved [1]
Erythema multiforme N.A. Approved [1]
Exanthem N.A. Approved [1]
Fever MG26 Approved [1]
Granuloma annulare N.A. Approved [1]
Hypersensitivity pneumonitis N.A. Approved [1]
Inflammatory bowel disease DD72 Approved [1]
Ischemia-reperfusion injury DB98.B Approved [1]
Keratitis N.A. Approved [1]
Leukemia N.A. Approved [1]
Lupus nephritis 4A40.0Y Approved [1]
Microscopic polyangiitis N.A. Approved [1]
Miliary tuberculosis N.A. Approved [1]
Mycosis fungoides 2B01 Approved [1]
Myeloproliferative neoplasm 2A20 Approved [1]
Pneumocystis pneumonia CA40.20 Approved [1]
Polymyalgia rheumatica N.A. Approved [1]
Primary cutaneous T-cell lymphoma N.A. Approved [1]
Psoriasis EA90 Approved [1]
Psoriatic arthritis FA21 Approved [1]
Rheumatic heart disease N.A. Approved [1]
Rosacea ED90.0 Approved [1]
Sarcoidosis 4B20.5 Approved [1]
Serum sickness N.A. Approved [1]
Severe asthma CA23 Approved [1]
Skin disease EA00-EM0Z Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Sympathetic ophthalmia N.A. Approved [1]
Systemic lupus erythematosus 4A40.0 Approved [1]
Ulcerative colitis DD71 Approved [1]
Multiple sclerosis 8A40 Phase 3 [3]
Acquired thrombocytopenia N.A. Investigative [1]
Asthma CA23 Investigative [1]
Beta-thalassemia major N.A. Investigative [1]
Classic Hodgkin lymphoma N.A. Investigative [1]
Follicular lymphoma 2A80 Investigative [1]
Iridocyclitis N.A. Investigative [1]
Sjogren syndrome 4A43.20 Investigative [1]
Synovitis N.A. Investigative [1]
Uveitis 9A96.Z Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 360.4
Logarithm of the Partition Coefficient (xlogp) 1.6
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 113-1343 mcg/L [4]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.0-2.6 h [4]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Bioavailability
The bioavailability of drug is 70% [4]
Clearance
The clearance of drug is 0.09 L/h/kg [4]
Elimination
The drug is over 98% eliminated in urine [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.1 - 3.5 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 9.23834 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.25% [7]
Vd
The volume of distribution (Vd) of drug is 29.3 L [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.38 mg/mL [5]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Apoptosis Not Available TOP1 OT51O0CF [8]
Metabolic disorder Not Available SMAD1 BSP1 MADH1 MADR1 OTQSHR25 [8]
Metabolic disorder Not Available CTNNB1 CTNNB OK/SW-cl.35 PRO2286 OTZ932A3 [8]
Chemical Identifiers
Formula
C21H28O5
IUPAC Name
(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
Canonical SMILES
C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
InChIKey
OIGNJSKKLXVSLS-VWUMJDOOSA-N
Cross-matching ID
PubChem CID
5755
ChEBI ID
CHEBI:8378
CAS Number
50-24-8
DrugBank ID
DB00860
TTD ID
D0D1SG
VARIDT ID
DR00428
INTEDE ID
DR1332
ACDINA ID
D00551
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [11]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Gene/Protein Processing [13]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Regulation of Drug Effects [14]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Gene/Protein Processing [13]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Gene/Protein Processing [13]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Gene/Protein Processing [13]
Albumin (ALB) OTVMM513 ALBU_HUMAN Gene/Protein Processing [15]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Gene/Protein Processing [13]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Gene/Protein Processing [13]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Gene/Protein Processing [13]
Antiviral innate immune response receptor RIG-I (RIGI) OTFIIC43 RIGI_HUMAN Gene/Protein Processing [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Prednisolone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Prednisolone caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [16]
Armodafinil DMGB035 Minor Increased metabolism of Prednisolone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [17]
LEE011 DMMX75K Moderate Decreased metabolism of Prednisolone caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [18]
Coadministration of a Drug Treating the Disease Different from Prednisolone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Minor Decreased absorption of Prednisolone due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [19]
Arn-509 DMT81LZ Moderate Accelerated clearance of Prednisolone due to the transporter induction by Arn-509. Acute myeloid leukaemia [2A60] [20]
Posaconazole DMUL5EW Moderate Decreased metabolism of Prednisolone caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [21]
Levalbuterol DM5YBO1 Minor Increased risk of hypokalemia by the combination of Prednisolone and Levalbuterol. Asthma [CA23] [16]
Terbutaline DMD4381 Minor Increased risk of hypokalemia by the combination of Prednisolone and Terbutaline. Asthma [CA23] [21]
Pirbuterol DMI5678 Minor Increased risk of hypokalemia by the combination of Prednisolone and Pirbuterol. Asthma [CA23] [21]
Salbutamol DMN9CWF Minor Increased risk of hypokalemia by the combination of Prednisolone and Salbutamol. Asthma [CA23] [16]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Prednisolone and Roflumilast. Asthma [CA23] [20]
Formoterol DMSOURV Minor Increased risk of hypokalemia by the combination of Prednisolone and Formoterol. Asthma [CA23] [21]
Ofloxacin DM0VQN3 Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Ofloxacin. Bacterial infection [1A00-1C4Z] [22]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Prednisolone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [23]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Prednisolone caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Sparfloxacin DMB4HCT Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Sparfloxacin. Bacterial infection [1A00-1C4Z] [22]
Gemifloxacin DMHT34O Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Gemifloxacin. Bacterial infection [1A00-1C4Z] [22]
Norfloxacin DMIZ6W2 Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Norfloxacin. Bacterial infection [1A00-1C4Z] [22]
ABT-492 DMJFD2I Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and ABT-492. Bacterial infection [1A00-1C4Z] [22]
Levofloxacin DMS60RB Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Levofloxacin. Bacterial infection [1A00-1C4Z] [22]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Prednisolone caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [24]
Lomefloxacin DMVRH9C Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Lomefloxacin. Bacterial infection [1A00-1C4Z] [22]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Prednisolone caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [21]
Tucatinib DMBESUA Moderate Decreased metabolism of Prednisolone caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [21]
Vilanterol DMF5EK1 Minor Increased risk of hypokalemia by the combination of Prednisolone and Vilanterol. Chronic obstructive pulmonary disease [CA22] [16]
Salmeterol DMIEU69 Minor Increased risk of hypokalemia by the combination of Prednisolone and Salmeterol. Chronic obstructive pulmonary disease [CA22] [21]
Indacaterol DMQJHR7 Minor Increased risk of hypokalemia by the combination of Prednisolone and Indacaterol. Chronic obstructive pulmonary disease [CA22] [21]
Arformoterol DMYM974 Minor Increased risk of hypokalemia by the combination of Prednisolone and Arformoterol. Chronic obstructive pulmonary disease [CA22] [21]
Ketoprofen DMRKXPT Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Ketoprofen. Chronic pain [MG30] [25]
Isoproterenol DMK7MEY Minor Increased risk of hypokalemia by the combination of Prednisolone and Isoproterenol. Conduction disorder [BC63] [16]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Prednisolone and Mivacurium. Corneal disease [9A76-9A78] [21]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Prednisolone and Pancuronium. Corneal disease [9A76-9A78] [21]
Tubocurarine DMBZIVP Moderate Additive neuromuscular blocking effects by the combination of Prednisolone and Tubocurarine. Corneal disease [9A76-9A78] [21]
Ivacaftor DMZC1HS Moderate Decreased clearance of Prednisolone due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [26]
MK-8228 DMOB58Q Moderate Decreased metabolism of Prednisolone caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [27]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Prednisolone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [21]
Zonisamide DM0DTF7 Moderate Increased metabolism of Prednisolone caused by Zonisamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Cenobamate DM8KLU9 Moderate Increased metabolism of Prednisolone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [29]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Prednisolone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [30]
Rufinamide DMWE60C Moderate Increased metabolism of Prednisolone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [20]
Phenobarbital DMXZOCG Moderate Increased metabolism of Prednisolone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [31]
Tazemetostat DMWP1BH Moderate Increased metabolism of Prednisolone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [32]
Itraconazole DMCR1MV Moderate Decreased metabolism of Prednisolone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [21]
Miconazole DMPMYE8 Moderate Decreased metabolism of Prednisolone caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [24]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Prednisolone caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [21]
Boceprevir DMBSHMF Moderate Decreased metabolism of Prednisolone caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [21]
Telaprevir DMMRV29 Moderate Decreased metabolism of Prednisolone caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [33]
Rifampin DMA8J1G Moderate Increased metabolism of Prednisolone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [34]
Rifapentine DMCHV4I Moderate Increased metabolism of Prednisolone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [35]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Prednisolone caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Prednisolone caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Saquinavir DMG814N Moderate Decreased metabolism of Prednisolone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Etravirine DMGV8QU Moderate Increased metabolism of Prednisolone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [36]
Darunavir DMN3GCH Moderate Decreased metabolism of Prednisolone caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Atazanavir DMSYRBX Moderate Decreased metabolism of Prednisolone caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [21]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [37]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Prednisolone and Teriflunomide. Hyper-lipoproteinaemia [5C80] [38]
Conivaptan DM1V329 Moderate Decreased metabolism of Prednisolone caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [21]
Meclofenamic acid DM05FXR Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [39]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Prednisolone caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [40]
Amobarbital DM0GQ8N Moderate Increased metabolism of Prednisolone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Zaleplon DMGFWSM Minor Increased metabolism of Prednisolone caused by Zaleplon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [41]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Prednisolone and Denosumab. Low bone mass disorder [FB83] [42]
Ceritinib DMB920Z Moderate Decreased metabolism of Prednisolone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [21]
PF-06463922 DMKM7EW Moderate Increased metabolism of Prednisolone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [43]
Selpercatinib DMZR15V Moderate Decreased metabolism of Prednisolone caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [20]
Idelalisib DM602WT Moderate Decreased metabolism of Prednisolone caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [21]
IPI-145 DMWA24P Moderate Decreased metabolism of Prednisolone caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [44]
Nivolumab DMAB9QE Moderate Additive immunosuppressive effects by the combination of Prednisolone and Nivolumab. Melanoma [2C30] [21]
Pembrolizumab DMFQEA6 Moderate Additive immunosuppressive effects by the combination of Prednisolone and Pembrolizumab. Melanoma [2C30] [21]
Ipilimumab DMJTIYK Moderate Additive immunosuppressive effects by the combination of Prednisolone and Ipilimumab. Melanoma [2C30] [21]
Cemiplimab DMKMJHE Moderate Additive immunosuppressive effects by the combination of Prednisolone and Cemiplimab. Melanoma [2C30] [21]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Prednisolone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [20]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Prednisolone and Thalidomide. Multiple myeloma [2A83] [45]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Prednisolone and Tecfidera. Multiple sclerosis [8A40] [46]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Prednisolone and Siponimod. Multiple sclerosis [8A40] [16]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Prednisolone and Fingolimod. Multiple sclerosis [8A40] [47]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Prednisolone and Ocrelizumab. Multiple sclerosis [8A40] [48]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Prednisolone and Ozanimod. Multiple sclerosis [8A40] [20]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Prednisolone caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [21]
Nilotinib DM7HXWT Moderate Decreased metabolism of Prednisolone caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [49]
Dasatinib DMJV2EK Moderate Decreased metabolism of Prednisolone caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [50]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Prednisolone and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [51]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Prednisolone and Bupropion. Nicotine use disorder [6C4A] [52]
Atezolizumab DMMF8U0 Moderate Additive immunosuppressive effects by the combination of Prednisolone and Atezolizumab. Non-small cell lung cancer [2C25] [21]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Prednisolone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [53]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Aspirin. Pain [MG30-MG3Z] [54]
Diflunisal DM7EN8I Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Diflunisal. Pain [MG30-MG3Z] [25]
Ibuprofen DM8VCBE Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Ibuprofen. Pain [MG30-MG3Z] [25]
Abametapir DM2RX0I Moderate Decreased metabolism of Prednisolone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [55]
Lefamulin DME6G97 Moderate Decreased metabolism of Prednisolone caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [56]
Choline salicylate DM8P137 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Choline salicylate. Postoperative inflammation [1A00-CA43] [57]
Bromfenac DMKB79O Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Bromfenac. Postoperative inflammation [1A00-CA43] [25]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Prednisolone caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [21]
Ritodrine DM4V6RL Minor Increased risk of hypokalemia by the combination of Prednisolone and Ritodrine. Preterm labour/delivery [JB00] [21]
Enzalutamide DMGL19D Moderate Increased metabolism of Prednisolone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [58]
Gatifloxacin DMSL679 Major Increased risk of tendinitis/tendon rupture by the combination of Prednisolone and Gatifloxacin. Respiratory infection [CA07-CA4Z] [22]
Salsalate DM13P4C Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Salsalate. Rheumatoid arthritis [FA20] [57]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Prednisolone and Canakinumab. Rheumatoid arthritis [FA20] [59]
Oxaprozin DM9UB0P Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Oxaprozin. Rheumatoid arthritis [FA20] [25]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Prednisolone and Rilonacept. Rheumatoid arthritis [FA20] [59]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Prednisolone and Golimumab. Rheumatoid arthritis [FA20] [60]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Prednisolone and Leflunomide. Rheumatoid arthritis [FA20] [38]
Salicyclic acid DM2F8XZ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Salicyclic acid. Seborrhoeic dermatitis [EA81] [54]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Prednisolone when combined with Anthrax vaccine. Sepsis [1G40-1G41] [61]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Prednisolone caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [21]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Prednisolone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [20]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Prednisolone and Pitolisant. Somnolence [MG42] [20]
Fostamatinib DM6AUHV Moderate Decreased clearance of Prednisolone due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [62]
Pipecuronium DM5F84A Moderate Additive neuromuscular blocking effects by the combination of Prednisolone and Pipecuronium. Tonus and reflex abnormality [MB47] [21]
Doxacurium DMKE7L9 Moderate Additive neuromuscular blocking effects by the combination of Prednisolone and Doxacurium. Tonus and reflex abnormality [MB47] [21]
Vecuronium DMP0UK2 Moderate Additive neuromuscular blocking effects by the combination of Prednisolone and Vecuronium. Tonus and reflex abnormality [MB47] [21]
Durvalumab DM4PVDY Moderate Additive immunosuppressive effects by the combination of Prednisolone and Durvalumab. Ureteral cancer [2C92] [21]
⏷ Show the Full List of 110 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Alpha-tocopherol E00243 14985 Antimicrobial preservative; Antioxidant
Butylated hydroxytoluene E00336 31404 Antioxidant
Docusate sodium E00563 23673837 Surfactant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Prednisolone 10 mg tablet 10 mg Disintegrating Oral Tablet Oral
Prednisolone 15 mg tablet 15 mg Disintegrating Oral Tablet Oral
Prednisolone 30 mg tablet 30 mg Disintegrating Oral Tablet Oral
Prednisolone 20 mg tablet 20 mg Oral Tablet Oral
Prednisolone 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Prednisolone FDA Label
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2866).
4 Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1979 Mar-Apr;4(2):111-28. doi: 10.2165/00003088-197904020-00004.
5 BDDCS applied to over 900 drugs
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
9 Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
10 The role of the efflux transporter P-glycoprotein in brain penetration of prednisolone. J Endocrinol. 2002 Oct;175(1):251-60.
11 Inter-individual difference determinant of prednisolone pharmacokinetics for Japanese renal transplant recipients in the maintenance stage. Xenobiotica. 2009 Dec;39(12):939-45.
12 Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats. J Pharmacokinet Biopharm. 1999 Feb;27(1):1-21.
13 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
14 Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
15 Prednisolone can increase glomerular permeability to proteins in nephrotic syndrome. Kidney Int. 1988 Jun;33(6):1169-74. doi: 10.1038/ki.1988.126.
16 Cerner Multum, Inc. "Australian Product Information.".
17 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
18 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
19 Albin H, Vincon G, Demotes-Mainard F, et al "Effect of aluminium phosphate on the bioavailability of cimetidine and prednisolone." Eur J Clin Pharmacol 26 (1984): 271-3. [PMID: 6723769]
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
22 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
23 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
24 Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease." Clin Pharmacokinet 43 (2004): 803-21. [PMID: 15355126]
25 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
26 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
27 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
28 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
29 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
30 Frey BM, Frey FJ "Phenytoin modulates the pharmacokinetics of prednisolone and the pharmacodynamics of prednisolone as assessed by the inhibition of the mixed lymphocyte reaction in humans." Eur J Clin Invest 14 (1984): 1-6. [PMID: 6230241]
31 Bartoszek M, Brenner AM, Szefler SJ "Prednisolone and methylprednisolone kinetics in children receiving anticonvulsant therapy." Clin Pharmacol Ther 42 (1987): 424-32. [PMID: 3665340]
32 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
33 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
34 Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
35 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
36 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
37 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
38 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
39 Messer J, Reitman D, Sacks HS, et al "Association of adrenocorticosteroid therapy and peptic-ulcer disease." N Engl J Med 309 (1983): 21-4. [PMID: 6343871]
40 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
41 Product Information. Sonata (zaleplon) Wyeth-Ayerst Laboratories, Philadelphia, PA.
42 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
43 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
45 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
46 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
47 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
48 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
49 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
50 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
51 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
52 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
53 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
54 Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
55 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
56 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
57 Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
58 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
59 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
60 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
61 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
62 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.